Clinical trial
Efficacy and Safety of Two Doses of Liarozole vs. Placebo for the Treatment of…
NCT00282724 · Stiefel, a GSK Company, Industry · Completed
Key facts
| NCT number | NCT00282724 |
|---|---|
| Title | Efficacy and Safety of Two Doses of Liarozole vs. Placebo for the Treatment of Lamellar Ichthyosis |
| Official title | A Randomized, Double-blind, Placebo-controlled Phase II/III Trial to Evaluate the Efficacy and Safety of 2 Doses of Oral Liarozole (75 mg od and 150 mg od) Given During 12 Weeks in Lamellar Ichthyosis |
| Lead sponsor | Stiefel, a GSK Company, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Ichthyosis, Lamellar |
| Intervention type | Drug |
| Interventions | Liarozole |
| Enrollment | 98 |
| Start date | Jan 1, 2006 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Jan 27, 2006 |
| Last update posted | Sep 26, 2011 |
| Countries | Belgium, Canada, Dominican Republic, France, Germany, Italy, Netherlands, Norway, Sweden |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: